

**Filed On Behalf Of:**  
Novartis AG

**By:**  
Nicholas N. Kallas  
NKallas@fchs.com  
ZortressAfinitorIPR@fchs.com  
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**PAR PHARMACEUTICAL, INC.,  
BRECKENRDIGE PHARMACEUTICAL, INC., AND  
ROXANE LABORATORIES, INC.,**  
Petitioners,

v.

**NOVARTIS AG,**  
Patent Owner.

---

Case IPR2016-00084<sup>1</sup>  
Patent No. 5,665,772

---

**PATENT OWNER'S EXHIBIT LIST 6**

---

<sup>1</sup> Breckenridge Pharmaceutical, Inc. was joined as a party to this proceeding via a Motion for Joinder in IPR2016-01023; Roxane Laboratories, Inc. was joined as a party via a Motion for Joinder in IPR2016-01102.

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2001</b>	Mason J., "Cyclosporins Past, Present, and Future," <i>Transplant. Proc.</i> 24(4) (Suppl. 2):61-63 (1992)	<b>Mason</b>
<b>2002</b>	Wenk, M. <i>et al.</i> , "Pharmacokinetics of Cyclosporine G in Patients with Renal Failure," <i>Transplantation</i> 45(3):558-61 (1988)	<b>Wenk</b>
<b>2003</b>	Traber, R. <i>et al.</i> , "Cyclosporins—New Analogues by Precursor Directed Biosynthesis," <i>Journal of Antibiotics</i> 42(4):591-97 (1989)	<b>Traber</b>
<b>2004</b>	Borel, J., "The Cyclosporins," <i>Transplant. Proc.</i> 21(1):810-15 (1989)	<b>Borel</b>
<b>2005</b>	Rozycki, J. <i>et al.</i> , "New Cyclosporin A Analogue: Synthesis and Immunosuppressive Activity," <i>Molecular Immunology</i> 29(9):1043-47 (1992)	<b>Rozycki</b>
<b>2006</b>	U.S. Patent No. 4,764,503	<b>'503 patent</b>
<b>2007</b>	U.S. Patent No. 4,885,276	<b>'276 patent</b>
<b>2008</b>	U.S. Patent No. 5,116,816	<b>'816 patent</b>
<b>2009</b>	U.S. Patent No. 5,122,511	<b>'511 patent</b>

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2010</b>	Rosen, M. & Schreiber, S., "Natural Products as Probes of Cellular Function: Studies of Immunophilins," <i>Angew. Chem. Int. Ed. Engl.</i> 31:384-400 (1992)	<b>Rosen</b>
<b>2011</b>	Fagioli, S. <i>et al.</i> , "FK 506: A New Immunosuppressive Agent for Organ Transplantation. Pharmacology, Mechanism of Action and Clinical Applications," <i>Ital. J. Gastroenterol.</i> 24(6):355-60 (1992)	<b>Fagioli</b>
<b>2012</b>	Keeffe, E. B., "Liver Transplantation—Challenges for the Future," <i>Western Journal of Medicine</i> 155(5):541-44 (1991)	<b>Keeffe</b>
<b>2013</b>	U.S. Patent No. 5,068,323	<b>'323 patent</b>
<b>2014</b>	U.S. Patent No. 4,980,466	<b>'466 patent</b>
<b>2015</b>	U.S. Patent No. 5,143,918	<b>'918 patent</b>
<b>2016</b>	U.S. Patent No. 4,929,611	<b>'611 patent</b>
<b>2017</b>	U.S. Patent No. 5,011,844	<b>'844 patent</b>
<b>2018</b>	EP 0 427 680	<b>EP 680</b>
<b>2019</b>	Carpenter, C. B., "Immunosuppression in Organ Transplantation," <i>New Eng. J.</i>	<b>Carpenter</b>

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
	<i>Med.</i> 322(17):1224-26 (1990)	
<b>2020</b>	Parlevliet, K. J. & Schellekens, P. T. A., "Monoclonal Antibodies in Renal Transplantation: A Review," <i>Transplant. Int.</i> 5(4):234-46 (1992)	<b>Parlevliet</b>
<b>2021</b>	Cramer, D. V. <i>et al.</i> , "The Effect of a New Immunosuppressive Drug, Brequinar Sodium, on Heart, Liver, and Kidney Allograft Rejection in the Rat," <i>Transplantation</i> , 53(2):303-08 (1992)	<b>Cramer</b>
<b>2022</b>	Bartlett, R. R. <i>et al.</i> , "Leflunomide (HWA 486), a Novel Immunomodulating Compound for the Treatment of Autoimmune Disorders and Reactions Leading to Transplantation Rejection," <i>Agents and Actions</i> 32(1/2):10-21 (1991)	<b>Bartlett</b>
<b>2023</b>	Sollinger, H. W. <i>et al.</i> , "RS-61443 (Mycophenolate Mofetil): A Multicenter Study for Refractory Kidney Transplant Rejection," <i>Ann. Surg.</i> 216(4):513-19 (1992)	<b>Sollinger</b>
<b>2024</b>	Mita K. <i>et al.</i> , "Advantages of Mizoribine Over Azathioprine in Combination Therapy With Cyclosporine for Renal Transplantation," <i>Transplant. Proc.</i> 22(4):1679-81 (1990)	<b>Mita</b>

<b>Exhibit</b>	<b>Description</b>	<b>Abbreviation</b>
<b>2025</b>	Iino, Y. <i>et al.</i> , “Improvement of Renal Function in Transplanted Kidneys with a New Immunosuppressive Drug, 15-Deoxyspergualin: Treatment of Chronic Rejection,” <i>Transplant. Proc.</i> 24(4):1381-82 (1992)	<b>Iino</b>
<b>2026</b>	U.S. Patent No. 4,952,579	<b>'579 patent</b>
<b>2027</b>	U.S. Patent No. 5,061,787	<b>'787 patent</b>
<b>2028</b>	U.S. Patent No. 5,137,917	<b>'917 patent</b>
<b>2029</b>	EP 0 181 592	<b>EP 592</b>
<b>2030</b>	U.S. Patent No. 4,847,381	<b>'381 patent</b>
<b>2031</b>	U.S. Patent No. 4,968,701	<b>'701 patent</b>
<b>2032</b>	Aulton, M. E. (Ed.), Chapters 3, 6, 8, 14, <i>Pharmaceutics: The Science of Dosage Form Design</i> (1988)	<b>Aulton</b>
<b>2033</b>	Silverman, R.B., Chapter 8, “Prodrugs and Drug Delivery Systems,” <i>The Organic Chemistry of Drug Design and Drug Action</i> (1992)	<b>Silverman</b>
<b>2034</b>	Ansel, H. & Popovich, N., Chapter 4, “Dosage Form Design: Biopharmaceutic Considerations,” <i>Pharmaceutical Dosage</i>	<b>Ansel</b>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.